Quick Answer
MBX Biosciences, Inc. reported Operating Income of -$98.06 million for fiscal year 2025.
MBX Biosciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$98.06M | -43.8% |
| 2024 | -$68.19M | -93.1% |
| 2023 | -$35.31M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$23.93M | -22.0% | -9.7% |
| June 30, 2025 | -$21.80M | -30.9% | +17.8% |
| March 31, 2025 | -$26.53M | -99.3% | -35.3% |
| September 30, 2024 | -$19.61M | -79.2% | -17.7% |
| June 30, 2024 | -$16.66M | — | -25.1% |
| March 31, 2024 | -$13.31M | — | -21.6% |
| September 30, 2023 | -$10.95M | — | — |
- MBX Biosciences, Inc. showed a decrease of -43.8% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, MBX Biosciences, Inc.’s operating income has declined by 177.7% (from -$35.31 million to -$98.06 million).
- The most recent figure is from MBX Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: